Company Description
Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States.
It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.
The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018.
Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.
| Country | United States |
| Founded | 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 371 |
| CEO | Nicholas Green |
Contact Details
Address: 14191 Myford Road Tustin, California 92780 United States | |
| Phone | 714 508 6100 |
| Website | avidbio.com |
Stock Details
| Ticker Symbol | CDMO |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0000704562 |
| CUSIP Number | 05368M106 |
| ISIN Number | US05368M1062 |
| Employer ID | 95-3698422 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nicholas Stewart Green B.Sc., MBA | President, Chief Executive Officer and Director |
| Daniel R. Hart | Chief Financial Officer |
| Richard A. Richieri | Chief Operations Officer |
| Mark R. Ziebell J.D. | Vice President, General Counsel and Corporate Secretary |
| Matthew R. Kwietniak | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | 144 | Filing |
| Dec 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 18, 2024 | DEFM14A | Filing |
| Dec 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 10, 2024 | 10-Q | Quarterly Report |
| Dec 10, 2024 | 8-K | Current Report |
| Dec 3, 2024 | PREM14A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |